Until now, no formulation that combined RA and TGFβ together with a T1D-relevant autoantigen, to induce antigen-specific immune hyporesponsiveness, was considered as a potential therapeutic vehicle. The gene discussed is TGFB1; the disease is type 1 diabetes mellitus.